STRO
Sutro Biopharma
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 3
Sell signal 1
stock price surged significantly
Revenue Beats Expectation
EPS Beats Expectation
RSI Overbought
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About STRO
Sutro Biopharma, Inc.
A clinical-stage oncology company that pioneering site-specific and novel-format antibody drug conjugates
111 Oyster Point Blvd., South San Francisco, California 94080
--
Sutro Biopharma, Inc., was incorporated under the laws of the State of Delaware on April 21, 2003, formerly known as Fundamental Applied Biology, Inc. The Company is a clinical-stage oncology company developing site-specific and novel antibody-drug conjugates through its proprietary integrated cell-free protein synthesis platform XpressCF and site-specific binding platform XpressCF +. The company's goal is to design and develop treatments that use the most relevant and effective modalities, including ADCs, bispecific ADCs, immunostimulating ADCs or iADCs, bi-conjugate ADCs or ADC2, and cytokine derivatives. The Company's most advanced product candidate is STRO-002, or luveltamab tazevibulin, or luvelta, an ADC targeting folate receptor-α, or FolRα, for cancer patients expressing FolRα, including ovarian cancer.
Company Financials
EPS
STRO has released its 2024 Q4 earnings. EPS was reported at -0.89, versus the expected -0.95, beating expectations. The chart below visualizes how STRO has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
STRO has released its 2024 Q4 earnings report, with revenue of 14.81M, reflecting a YoY change of -86.98%, and net profit of -72.44M, showing a YoY change of -333.20%. The Sankey diagram below clearly presents STRO’s revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
